Stock of the We: Merck & Co. Inc
Merck’s recent financial performance and strategic moves make it a compelling stock for investors.
The company reported a 7% increase in total worldwide sales for Q2 2024, reaching $16.1 billion, with significant growth in its flagship cancer drug, Keytruda, which saw a 16% rise in sales. The introduction of Winrevair, a new treatment for pulmonary arterial hypertension, also exceeded expectations, adding a promising new revenue stream.
Despite a lowered full-year guidance due to acquisition costs and foreign exchange impacts, Merck’s fundamentals remain strong. The company’s non-GAAP EPS was $2.28, beating Wall Street’s expectations, and its strong pipeline, including recent successes in vaccine programs and oncology, continues to show potential for long-term growth. Notably, Merck’s recent acquisitions and ongoing product launches position it well in a competitive market.
Merck’s stock fell after adjusting its 2024 earnings outlook, mainly due to a one-time charge related to the EyeBio acquisition. However, analysts maintain a positive long-term view, citing the temporary nature of these impacts and the robust performance of key products like Keytruda. The company’s focus on innovation and market expansion, particularly in the biopharma sector, supports a bullish outlook.
Here is how the bank analysts view the company currently:
The consensus of the bank analysts is “Buy.” Out of the 28 analysts covering the share, 23 rate the stock with “Buy,” 5 with “Hold,” and no analyst recommends selling the stock.
The average expected upside of the stock price for the next six to twelve months is currently ca 24.7% (closing price on 30.07.2024).
Sources:
